 The purpose of this study is to evaluate if the addition of Bortezomib Velcade to IGEV combination Ifosfamide, Gemcitabine and Vinorelbine in patients with relapsedrefractory Hodgkins lymphoma increases the rate of complete remission PET negativity at transplantation. 